Slight boost for Galenica
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Galenica said it had achieved “solid growth in what continued to be a very challenging market environment” as it reported its 2018 first-half results. “Sales growth was slowed by additional price reduction measures for medications, which were significantly higher than originally announced by the authorities,” the Swiss company noted.